{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:36:48Z","timestamp":1794224208909,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41401-020-00511-5","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T04:02:25Z","timestamp":1599710545000},"page":"824-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Feasibility study of 68Ga-labeled CAR\u00a0T cells for in vivo tracking using micro-positron emission tomography imaging"],"prefix":"10.1038","volume":"42","author":[{"given":"Xin-yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-hui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-ji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-yan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"511_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"511_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"key":"511_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"511_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423\u201331.","journal-title":"Nature"},{"key":"511_CR5","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","volume":"318","author":"PB Bach","year":"2017","unstructured":"Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318:1861\u20132.","journal-title":"JAMA"},{"key":"511_CR6","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","volume":"25","author":"N Bouchkouj","year":"2019","unstructured":"Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019;25:1702\u20138.","journal-title":"Clin Cancer Res"},{"key":"511_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrd.2018.4","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard A. 2017 FDA drug approvals. Nat Rev Drug Discov. 2018;17:81\u20135.","journal-title":"Nat Rev Drug Discov"},{"key":"511_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183:364\u201374.","journal-title":"Br J Haematol"},{"key":"511_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol."},{"key":"511_CR10","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"511_CR11","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317\u201325.","journal-title":"Blood"},{"key":"511_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RP, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25:2245\u201353.","journal-title":"Mol Ther."},{"key":"511_CR13","doi-asserted-by":"publisher","first-page":"e90064","DOI":"10.1172\/jci.insight.90064","volume":"1","author":"Y Vedvyas","year":"2016","unstructured":"Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight. 2016;1:e90064.","journal-title":"JCI Insight"},{"key":"511_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E, et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial. Blood. 2018;132:959.","journal-title":"Blood"},{"key":"511_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13139-014-0309-x","volume":"49","author":"JE Kim","year":"2015","unstructured":"Kim JE, Kalimuthu S, Ahn B-C. In vivo cell tracking with bioluminescence imaging. Nuc Med Mol Imaging. 2015;49:3\u201310.","journal-title":"Nuc Med Mol Imaging."},{"key":"511_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nri3531","volume":"13","author":"ET Ahrens","year":"2013","unstructured":"Ahrens ET, Bulte JW. Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol. 2013;13:755\u201363.","journal-title":"Nat Rev Immunol."},{"key":"511_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.addr.2010.08.009","volume":"62","author":"M Srinivas","year":"2010","unstructured":"Srinivas M, Aarntzen E, Bulte J, Oyen W, Heerschap A, De Vries I, et al. Imaging of cellular therapies. Adv Drug Deliv Rev. 2010;62:1080\u201393.","journal-title":"Adv Drug Deliv Rev."},{"key":"511_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrclinonc.2011.141","volume":"8","author":"MF Kircher","year":"2011","unstructured":"Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol. 2011;8:677\u201388.","journal-title":"Nat Rev Clin Oncol."},{"key":"511_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41401-019-0313-x","volume":"41","author":"F Wang","year":"2019","unstructured":"Wang F, Wang Z, Wang F, Dong K, Zhang J, Sun YJ, et al. Comparative strategies for stem cell biodistribution in a preclinical study. Acta Pharmacol Sin. 2019;41:572\u201380.","journal-title":"Acta Pharmacol Sin."},{"key":"511_CR20","first-page":"689","volume":"29","author":"MA Gainey","year":"1988","unstructured":"Gainey MA, Siegel JA, Smergel EM, Jara BJ. Indium-111-labeled white blood cells: dosimetry in children. J Nucl Med. 1988;29:689\u201394.","journal-title":"J Nucl Med."},{"key":"511_CR21","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/RLU.0b013e31821738a0","volume":"36","author":"M Djekidel","year":"2011","unstructured":"Djekidel M, Brown RK, Piert M. Benefits of hybrid SPECT\/CT for 111In-oxine-and Tc-99m-hexamethylpropylene amine oxime-labeled leukocyte imaging. Clin Nucl Med. 2011;36:e50\u2013e6.","journal-title":"Clin Nucl Med."},{"key":"511_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00259-014-2945-x","volume":"42","author":"P Charoenphun","year":"2015","unstructured":"Charoenphun P, Meszaros LK, Chuamsaamarkkee K, Sharif-Paghaleh E, Ballinger JR, Ferris TJ, et al. [89Zr] Oxinate 4 for long-term in vivo cell tracking by positron emission tomography. Eur J Nucl Med Mol Imaging. 2015;42:278\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"511_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2967\/jnumed.117.206714","volume":"59","author":"MR Weist","year":"2018","unstructured":"Weist MR, Starr R, Aguilar B, Chea J, Miles JK, Poku E, et al. PET of adoptively transferred chimeric antigen receptor T cells with 89Zr-oxine. J Nucl Med. 2018;59:1531\u20137.","journal-title":"J Nucl Med."},{"key":"511_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1148\/radiol.15142849","volume":"275","author":"N Sato","year":"2015","unstructured":"Sato N, Wu H, Asiedu KO, Szajek LP, Griffiths GL, Choyke PL. 89Zr-oxine complex PET cell imaging in monitoring cell-based therapies. Radiology. 2015;275:490\u2013500.","journal-title":"Radiology"},{"key":"511_CR25","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-19-2897","volume":"26","author":"N Sato","year":"2020","unstructured":"Sato N, Stringaris K, Davidson-Moncada JK, Reger R, Adler SS, Dunbar C, et al. In-vivo tracking of adoptively transferred natural killer-cells in rhesus macaques using 89Zirconium-oxine cell labeling and PET imaging. Clin Cancer Res. 2020;26:2573\u201381.","journal-title":"Clin Cancer Res."},{"key":"511_CR26","doi-asserted-by":"publisher","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","volume":"9","author":"KV Keu","year":"2017","unstructured":"Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017;9:eaag2196.","journal-title":"Sci Transl Med."},{"key":"511_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/cmmi.1540","volume":"8","author":"S Lacroix","year":"2013","unstructured":"Lacroix S, Egrise D, Van Simaeys G, Doumont G, Monclus M, Sherer F, et al. [18F]\u2010FBEM, a tracer targeting cell-surface protein thiols for cell trafficking imaging. Contrast Media Mol Imaging. 2013;8:409\u201316.","journal-title":"Contrast Media Mol Imaging"},{"key":"511_CR28","doi-asserted-by":"publisher","first-page":"eaaw5096","DOI":"10.1126\/sciadv.aaw5096","volume":"5","author":"I Minn","year":"2019","unstructured":"Minn I, Huss DJ, Ahn H-H, Chinn TM, Park A, Jones J, et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv. 2019;5:eaaw5096.","journal-title":"Sci Adv."},{"key":"511_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymthe.2018.10.006","volume":"27","author":"F Man","year":"2019","unstructured":"Man F, Lim L, Volpe A, Gabizon A, Shmeeda H, Draper B, et al. In vivo PET tracking of 89Zr-labeled V\u03b39V\u03b42 T cells to mouse xenograft breast tumors activated with liposomal alendronate. Mol Ther. 2019;27:219\u201329.","journal-title":"Mol Ther."},{"key":"511_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.nucmedbio.2019.04.001","volume":"71","author":"A Socan","year":"2019","unstructured":"Socan A, Petrik M, Peitl PK, Kro\u0161elj M, Rangger C, Novy Z, et al. On-cartridge preparation and evaluation of 68Ga-, 89Zr-and 64Cu-precursors for cell radiolabelling. Nucl Med Biol. 2019;71:23\u201331.","journal-title":"Nucl Med Biol."},{"key":"511_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","volume":"28","author":"MA Sellmyer","year":"2020","unstructured":"Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Mol Ther. 2020;28:42\u201351.","journal-title":"Mol Ther"},{"key":"511_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03524-1","volume":"9","author":"N Emami-Shahri","year":"2018","unstructured":"Emami-Shahri N, Foster J, Kashani R, Gazinska P, Cook C, Sosabowski J, et al. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat Commun. 2018;9:1081.","journal-title":"Nat Commun."},{"key":"511_CR33","doi-asserted-by":"publisher","first-page":"7924","DOI":"10.7150\/thno.37924","volume":"9","author":"M Krekorian","year":"2019","unstructured":"Krekorian M, Fruhwirth GO, Srinivas M, Figdor CG, Heskamp S, Witney TH, et al. Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics. 2019;9:7924.","journal-title":"Theranostics"},{"key":"511_CR34","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2174\/156802610793176738","volume":"10","author":"F Roesch","year":"2010","unstructured":"Roesch F, J Riss P. The renaissance of the 68Ge\/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr Top Med Chem. 2010;10:1633\u201368.","journal-title":"Curr Top Med Chem."},{"key":"511_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36:494\u2013502.","journal-title":"Trends Immunol."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00511-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00511-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T19:17:01Z","timestamp":1631042221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00511-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00511-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}